Literature DB >> 8090787

Identification of soluble forms of the fibroblast growth factor receptor in blood.

A Hanneken1, W Ying, N Ling, A Baird.   

Abstract

We have purified three acidic (FGF-1) and basic (FGF-2) fibroblast growth factor binding proteins (FGF-BP1, FGF-BP2, and FGF-BP3) from human plasma and calf serum and demonstrate the presence of these circulating FGF-BPs in blood. Each are truncated forms of the high-affinity FGF receptor (FGFR-1). FGF-BP1 and FGF-BP2 have estimated molecular masses of 70-85 kDa and 55-60 kDa, respectively, and are detected by using 125I-labeled FGF-2 ligand blotting. Immunoblotting with four distinct antibodies to FGFR-1 reveals that FGF-BP1 and FGF-BP2 are immunologically and biochemically related to the extracellular domain of FGFR-1. Reverse-phase HPLC chromatography resolves FGF-BP2 into two proteins with estimated molecular masses of 55 kDa and 60 kDa. Protein sequencing of the amino terminus of FGF-BP2 and FGF-BP3 reveals identity with the extracellular domain of the two-IgG-loop form of human FGFR-1. The FGF-BPs do not require heparin to bind FGF-2 on affinity columns, but heparin does enhance their recovery from blood. These FGF-BPs may play an important physiological role in regulating the biological activity of FGF and the other members of the FGF family of growth factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8090787      PMCID: PMC44769          DOI: 10.1073/pnas.91.19.9170

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Identification of a truncated form of the nerve growth factor receptor.

Authors:  P S DiStefano; E M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

2.  Growth hormone receptor and serum binding protein: purification, cloning and expression.

Authors:  D W Leung; S A Spencer; G Cachianes; R G Hammonds; C Collins; W J Henzel; R Barnard; M J Waters; W I Wood
Journal:  Nature       Date:  1987 Dec 10-16       Impact factor: 49.962

3.  Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer.

Authors:  G W Chodak; V Hospelhorn; S M Judge; R Mayforth; H Koeppen; J Sasse
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

4.  Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients.

Authors:  M Nguyen; H Watanabe; A E Budson; J P Richie; J Folkman
Journal:  J Natl Cancer Inst       Date:  1993-02-03       Impact factor: 13.506

5.  Polypeptide microsequence analysis with the commercially available gas-phase sequencer.

Authors:  F S Esch
Journal:  Anal Biochem       Date:  1984-01       Impact factor: 3.365

6.  Release of growth hormone binding protein from IM-9 lymphocytes by endopeptidase is dependent on sulfhydryl group inactivation.

Authors:  B Trivedi; W H Daughaday
Journal:  Endocrinology       Date:  1988-11       Impact factor: 4.736

7.  Glycosylation of the basic fibroblast growth factor receptor. The contribution of carbohydrate to receptor function.

Authors:  J J Feige; A Baird
Journal:  J Biol Chem       Date:  1988-10-05       Impact factor: 5.157

8.  Immunoreactive fibroblast growth factor (FGF) in rat tissues: molecular weight forms and the effects of hypophysectomy.

Authors:  P Mormède; A Baird; P Pigeon
Journal:  Biochem Biophys Res Commun       Date:  1985-05-16       Impact factor: 3.575

9.  Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line.

Authors:  L E Allen; P A Maher
Journal:  J Cell Physiol       Date:  1993-05       Impact factor: 6.384

10.  Multiple influences of a heparin-binding growth factor on neuronal development.

Authors:  D Schubert; N Ling; A Baird
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more
  21 in total

Review 1.  Molecular and cellular mechanisms of ectodomain shedding.

Authors:  Kazutaka Hayashida; Allison H Bartlett; Ye Chen; Pyong Woo Park
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

2.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.

Authors:  E Levi; R Fridman; H Q Miao; Y S Ma; A Yayon; I Vlodavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 3.  Ocular neovascularization: clarifying complex interactions.

Authors:  K A Neely; T W Gardner
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 4.  The molecular pathogenetic role of cell adhesion in endocrine neoplasia.

Authors:  S Ezzat; S L Asa
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

Review 5.  Design of growth factor sequestering biomaterials.

Authors:  David G Belair; Ngoc Nhi Le; William L Murphy
Journal:  Chem Commun (Camb)       Date:  2014-09-03       Impact factor: 6.222

Review 6.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis.

Authors:  Abha Sahni; Alok A Khorana; Raymond B Baggs; Hu Peng; Charles W Francis
Journal:  Blood       Date:  2005-09-13       Impact factor: 22.113

8.  FGF signaling is required for lens regeneration in Xenopus laevis.

Authors:  Lisa Fukui; Jonathan J Henry
Journal:  Biol Bull       Date:  2011-08       Impact factor: 1.818

9.  1α,25(OH)₂D₃ inhibits FGF-2 release from oral squamous cell carcinoma cells through down-regulation of HBp17/FGFBP-1.

Authors:  S N Zawani B Rosli; Tomoaki Shintani; Shigeaki Toratani; Emiko Usui; Tetsuji Okamoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-06-18       Impact factor: 2.416

Review 10.  The fibroblast growth factor family: neuromodulation of affective behavior.

Authors:  Cortney A Turner; Stanley J Watson; Huda Akil
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.